Ligand Pharmaceuticals (LGND)
NASDAQ: LGND
· Real-Time Price · USD
114.78
2.28 (2.03%)
At close: Jun 16, 2025, 3:59 PM
115.30
0.45%
After-hours: Jun 16, 2025, 04:27 PM EDT
2.03% (1D)
| Bid | 110.08 |
| Market Cap | 2.21B |
| Revenue (ttm) | 181.49M |
| Net Income (ttm) | -132.62M |
| EPS (ttm) | -7.29 |
| PE Ratio (ttm) | -15.74 |
| Forward PE | 16.13 |
| Analyst | Buy |
| Ask | 116.2 |
| Volume | 71,326 |
| Avg. Volume (20D) | 119,060 |
| Open | 113.53 |
| Previous Close | 112.50 |
| Day's Range | 112.56 - 115.19 |
| 52-Week Range | 77.53 - 129.90 |
| Beta | 0.71 |
About LGND
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LGND
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LGND stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+0.57%
Ligand Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
7 months ago
+11.12%
Ligand Pharmaceuticals shares are trading higher after the company reported worse-than-expected Q3 financial results and raised its FY24 guidance.
1 month ago · seekingalpha.com
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call TranscriptLigand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chie...